Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03980990

Enrollment

500

Registered

2019-06-10

Start date

2019-06-17

Completion date

2020-06-17

Last updated

2019-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Diabetes Mellitus, Metformin Adverse Reaction, Unstable Angina

Keywords

metformin, diabetes, pci, percutaneous coronary intervention, unstable angina, acute coronary syndrome

Brief summary

This pilot randomized controlled trial aims to evaluate the feasibility for safety examination of continued metformin therapy in patients with type 2 diabetes (T2D) following invasive coronary angiography. Metformin will be continued until coronary angiography.

Interventions

DRUGMetformin

Continuation of Metformin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years 2. On metformin therapy 3. Angiography for ACS or elective non-ACS related indications 4. Informed consent received

Exclusion criteria

1. Cardiogenic shock prior to randomization 2. Cardiac arrest prior to randomization 3. Established severe CKD (eGFR\<30, or on dialysis) 4. Chronic liver disease 5. Need for CABG within 48 hours of hospitalization 6. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated

Design outcomes

Primary

Measure	Time frame	Description
Lactic Acidosis	48-72 hours (or 72 hours for patients with staged PCI procedures within 48 hours of randomization)	Lactate Level \>5 mmol/L and HCO3\<18

Secondary

Measure	Time frame	Description
Acute Kidney Injury	48-72 hours (or 72 hours for patients with staged PCI procedures within 48 hours of randomization)	Rise in baseline creatinine \>/= 25% or 27 umol/L
All cause mortality at hospital discharge	Duration of hospital admission	Death in hospital

Countries

Canada

Contacts

Primary ContactJay Shavadia, MD

jss372@usask.ca3066553932

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026